Treatment of Epiretinal Membranes With Ranibizumab

Not Applicable

Completed

• Conditions: Epiretinal Membrane
• Interventions: Drug: intravitreal ranibizumab

• Registration Number: NCT01238393
• Lead Sponsor: Queen's University

Brief Summary

The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-09
• Study First Submitted QC: 2010-11-09
• Study First Posted: 2010-11-10
• Primary Completion: 2011-11
• Study Completion: 2012-01
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-12
• Last Update Posted: 2016-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• symptomatic idiopathic epiretinal membrane

Exclusion Criteria

• vision worse than 6/18 and fit for surgery
• prior vitreoretinal surgery or injection
• diabetes
• any past or current form of retinal vein occlusion or neovascularization
• age-related macular degeneration
• other condition causing significant limitation of visual potential

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ranibizumab	intravitreal ranibizumab	('intravitreal ranibizumab' )

Primary Outcome Measures

Name	Time	Method
Evidence of improvement measured by optical coherence tomography	3 and 6 months

Secondary Outcome Measures

Name	Time	Method
Subjective change in symptoms	3 and 6 months
Amsler grid improvement	3 and 6 months
Near visual acuity (Snellen)	3 and 6 months
Distance visual acuity (ETDRS)	3 and 6 months
Quality of life improvement	6 months

Trial Locations

Locations (1)

Queen's University, Hotel Dieu Hospital; 🇨🇦 Kingston, Ontario, Canada